2022
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model
Hinahara J, Weinzimer SA, Bromley ER, Goss TF, Kendall DM, Hammer M. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model. Journal Of Managed Care & Specialty Pharmacy 2022, 28: 10.18553/jmcp.2022.28.4.461. PMID: 35332789, PMCID: PMC10373001, DOI: 10.18553/jmcp.2022.28.4.461.Peer-Reviewed Original ResearchConceptsBudget impact modelHealth care resource utilizationSevere hypoglycemiaSH eventsGlucagon treatmentNasal glucagonUS commercial health planLower total health care costsSuccessful administrationTotal direct medical costsTotal health care costsPlasma glucose recoveryEmergency department visitsSevere hypoglycemic eventsInitial treatment successDirect medical costsCommercial health plansType 2 diabetesHealth care costsHealth economic modelEmergency medical servicesNative glucagonGlucagon analogsInjectable glucagonPrompt administration
2018
An Effective Diabetic Ketoacidosis Prevention Intervention in Children With Type 1 Diabetes
Vitale RJ, Card CE, Lichtman JH, Weyman K, Michaud C, Sikes K, Tamborlane WV, Weinzimer SA. An Effective Diabetic Ketoacidosis Prevention Intervention in Children With Type 1 Diabetes. SAGE Open Nursing 2018, 4: 2377960818804742. PMID: 33415207, PMCID: PMC7774356, DOI: 10.1177/2377960818804742.Peer-Reviewed Original ResearchSick-day managementEmergency department visitsDiabetic ketoacidosisDepartment visitsSymptoms of DKAEarly outpatient interventionEducational interventionShort educational interventionBrief refresher courseKnowledge of signsSame knowledge questionnaireParents of childrenTreatment modalitiesOutpatient interventionPrevention interventionsPatient recognitionKnowledge questionnaireType 1Sick daysEarly warning signsDay managementInterventionPatientsWarning signsSymptoms